Table 1 Identification of high risk human papilloma viruses in prostate cancer. Case control studies with normal and benign prostate tissues as controls

McNichol 1991 [12]

Canada

14/27 52%

1/5 20% normal

34/56 61% benign

16,18

0.396 ns

0.690 ns

Anwar 1992 [14]

Japan

28/68 41%

0/10 0%

16,18,33

0.221 ns

Ibrahim 1992 [15]

US

6/40 15%

2/29 7%

16

0.344 ns

Rotola 1992 [16]

Italy

6/8 75%

14/17 82%

16

0.0.815 ns

Dodd 1993 [17]

Canada

3/7 43%

5/10 50%

16

0.0.841 ns

Tu 1994 [18]

US

1/43

0/1

16

Moyret-Lalle 1995 [19]

France

9/17 53%

7/22 32%

16

0.682 ns

Wideroff 1996 [20]

US

7/56 13%

4/42 10%

16,18,31,33,45

0.654 ns

Terris 1997 [21]

US

10/53 19%

5/37 14% normal

7/21 33% benign

16

16

0.571 ns

Serth 1999 [22]

Germany

10/47 21%

1/37 3%

16

0.027 s

Carozzi 2004 [23]

Italy

6/24 25%

3/25 12%

16,18,31

0.333 ns

Leiros 2005 [24]

Argentina

15/41 37%

0/30 0%

16

0.011 s

Silvestre 2009 [25]

Brazil

2/65 3%

0/6 0%

16

Martinez-Fierro 2010 [26]

Mexico

11/55 20%

4/75 5%

33,45,52,58,66

0.020 s

Aghakhani 2011 [27]

Iran

10/104 10%

5/104 5%

16,18

0.213 ns

Chen 2011 [12]

Australia

7/51 14%

3/11 27%

18

0.367 ns

Tachezy 2012 [28]

Czech

1/51 2%

2/95 2%

Whitaker 2013 [29]

Australia

29/50 58%

8/50 16%

18

0.003 s

Ghasemian 2013 [30]

Iran

5/29 17%

8/167 5%

0.026 s

Mokhtari 2013 [31]

Iran

3/30 10%

1/90 1%

Michopoulou 2014 [32]

Greece

8/50 16%

1/30 3%

16, 18, 31

0.127 ns

Singh 2015 [33]

India

36/95 38%

4/55 7%

16,18

0.001 s

Huang 2016 [34]

China

30/75 40%

9/73 12%

0.001 s

Davila Rodriquez 2016 [35]

Mexico

12/62 19%

1/25 4%

18,51,52

0.104 ns

Atashafrooz 2016 [36]

Iran

16/100 16%

2/100 2%

16,18,31,33,54

0.002 s

Medel Flores 2018 [37]

Mexico

37/189 20%

16/167 10%

16,18,31,33,52,58

0.014 s